ArticleScientific reports2026
Enhancing wound healing with synergistic dual-drug electrospun roflumilast and L-arginine loaded PLA/PVA nanofibers through fabrication, optimization, and in vivo assessment.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Bioactive-Enriched Chitosan/Poly(vinyl Alcohol) Electrospun Nanofibers for Wound Healing: In Vitro and In Vivo Evaluation.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current trends in improved wound management emphasize the development of dual-drug-loaded electrospun nanofibrous scaffolds. Herein, electrospun dual-drug loaded PLA/PVA nanofibrous scaffolds, incorporating roflumilast, a selective phosphodiesterase-4 inhibitor with anti-inflammatory activity, and L-arginine, a precursor to nitric oxide with stimulating activity towards wound healing and tissue regeneration, were developed. A dual-spinneret electrospinning process enabled the co-loading of drugs in PLA and PVA phases. Scaffolds were characterized by SEM, FTIR, and XRD, showing consistent fiber morphology, and amorphous drug formation. FTIR analysis was performed to confirm drug-polymer compatibility and successful incorporation of roflumilast and L-arginine within the PLA/PVA nanofibrous matrix. Swelling ratio analysis indicated controlled hydration behavior regarding polymer-drug composition, and dual-drug-loaded fibers exhibited maximum initial swelling (610%) and stabilization at ~ 240%. In vivo rat excision wound healing model showed that the dual-drug loaded nanofibers demonstrated enhanced wound healing with ~ 99.8% healing on day 14, which was significantly better, compared to nanofibers incorporating a single drug and control groups. Moreover, histological studies revealed the absence of residual granulation tissue and enhanced re-epithelialization in the dual-drug treated group. These results indicate that roflumilast and L-arginine co-loaded PLA/PVA nanofibers exhibit wound-healing and regenerative properties, offering a promising therapeutic platform for enhanced wound repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.